Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,018 public trials 2,029 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours

NCT02343718

Conditions
Central Nervous System, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Children's and Women's Health Centre of BC Branch Vancouver, British Columbia, Canada
  • Izaak Walton Killam (IWK) Health Centre Halifax, Nova Scotia, Canada
  • McMaster Children's Hospital Hamilton, Ontario, Canada
  • Children's Hospital of Eastern Ontario Ottawa, Ontario, Canada
View Trial Details
Completed

Bortezomib in Treating Patients With Mantle Cell Lymphoma

NCT00030875

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • British Columbia Cancer Agency Vancouver, British Columbia, Canada
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
  • Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada
View Trial Details
Completed

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01145989

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Atlantic Health Sciences Corporation Saint John, New Brunswick, Canada
  • QEII Health Sciences Center Halifax, Nova Scotia, Canada
View Trial Details
Completed

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

NCT00305812

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tom Baker Cancer Centre - Calgary Calgary, Alberta, Canada
  • Cross Cancer Institute at University of Alberta Edmonton, Alberta, Canada
  • British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada
  • Moncton Hospital Moncton, New Brunswick, Canada
View all 14 locations
View Trial Details
Completed

Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)

NCT01936532

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHRU - Hôpital du Haut Lévêque Bordeaux, France
  • CHRU Dijon Dijon, France
  • Centre hospitalier départemental Vendée La Roche-sur-Yon, France
  • CHRU - Hôpital Claude Huriez Lille, France
View Trial Details

Related conditions